Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the target of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 2,750,000 shares, a decrease of 13.8% from the January 15th total of 3,190,000 shares. Based on an average daily trading volume, of 1,280,000 shares, the short-interest ratio is currently 2.1 days. Approximately 3.3% of the company’s shares are short sold.

Compass Therapeutics Trading Down 2.0 %

Compass Therapeutics stock opened at $3.38 on Tuesday. Compass Therapeutics has a 52-week low of $0.76 and a 52-week high of $4.08. The company’s 50 day moving average is $2.31 and its two-hundred day moving average is $1.83.

Institutional Investors Weigh In On Compass Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Rovin Capital UT ADV acquired a new stake in Compass Therapeutics during the 3rd quarter worth approximately $25,000. Tower Research Capital LLC TRC lifted its holdings in Compass Therapeutics by 298.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after buying an additional 12,917 shares in the last quarter. Independent Advisor Alliance acquired a new stake in shares of Compass Therapeutics in the 4th quarter valued at $26,000. BNP Paribas Financial Markets purchased a new stake in shares of Compass Therapeutics during the 4th quarter worth $27,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Compass Therapeutics during the 3rd quarter worth $30,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Leerink Partnrs cut shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. D. Boral Capital restated a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $5.00 to $4.00 in a report on Friday, November 15th. Jefferies Financial Group upped their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, February 10th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.17.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.